Only 1 of 25 cancer drug developers fairly included minority patients over five-year window, BMJ analysis finds
New clinical trial diversity plans, which FDA will soon explain further, were featured in the government spending package that President Joe Biden signed late last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
